🇺🇸 FDA
Pipeline program

Cenerimod 4 mg, Cenerimod matching placebo

ID-064A302

Phase 3 small_molecule active

Quick answer

Cenerimod 4 mg, Cenerimod matching placebo for Moderate to severe systemic lupus erythematosus is a Phase 3 program (small_molecule) at Viatris Pharmaceuticals Co., with 1 ClinicalTrials.gov record(s).

Program details

Company
Viatris Pharmaceuticals Co.,
Indication
Moderate to severe systemic lupus erythematosus
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials